Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer
Preprint
Abstract
Triple-negative breast cancer (TNBC) patients receive chemotherapy treatment, including doxorubicin, due to the lack of targeted therapies. Drug resistance is a major cause of treatment failure in TNBC and therefore, there is a need to identify biomarkers that determine effective drug response. Here, a pharmacometabolomics study was performed using TNBC patient-derived xenograft models to detect urinary metabolic biomarkers of doxorubicin effectiveness. Diacetylspermine was identified as a urine metabolite that robustly changed in response to effective doxorubicin treatment, which persisted after the final dose. Diacetylspermine was directly traced back to the tumor and correlated with tumor volume. Ex vivo tumor slices revealed that doxorubicin directly increases diacetylspermine production by increasing tumor spermidine/spermine N 1 -acetyltransferase 1 expression and activity, which was corroborated by elevated polyamine flux. In breast cancer patients, tumor diacetylspermine was elevated compared to matched non-cancerous tissue and increased in HER2+ and TNBC compared to ER+ subtypes. In addition, 12-hour urine diacetylspermine was associated with breast cancer tumor volume and poor tumor grade. This study describes a pharmacometabolomics strategy for identifying cancer metabolic biomarkers that indicate drug response. Our findings characterize urine diacetylspermine as a non-invasive biomarker of doxorubicin effectiveness in TNBC.Keywords
All Related Versions
- Published version: npj Precision Oncology, 6 (1), 1.
This publication has 39 references indexed in Scilit:
- Global Metabolomics Reveals Urinary Biomarkers of Breast Cancer in a MCF-7 Xenograft Mouse ModelMetabolites, 2013
- Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cellsMetabolomics, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Comprehensive Profiling and Quantitation of Amine Group Containing MetabolitesAnalytical Chemistry, 2011
- Metabolomic Analysis of Resveratrol-Induced Effects in the Human Breast Cancer Cell Lines MCF-7 and MDA-MB-231OMICS: A Journal of Integrative Biology, 2011
- A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by CultureIn vitroCancer Research, 2009
- Spermidine/spermine-N1-acetyltransferase: a key metabolic regulatorAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Established breast cancer risk factors by clinically important tumour characteristicsBritish Journal of Cancer, 2006
- Interaction of N1,N12-Diacetylspermine with Polyamine Transport Systems of Polarized Porcine Renal Cell Line LLC-PK1The Journal of Biochemistry, 2005
- Diagnostic and prognostic usefulness of N 1 , N 8 -diacetylspermidine and N 1 , N 12 -diacetylspermine in urine as novel markers of malignancyJournal of Cancer Research and Clinical Oncology, 1997